Biotech News

ImmunityBio Achieves Milestone with Large-Scale NK Cell Production and Cryopreservation from Over 60 Healthy and Cancer Donors

ImmunityBio (IBRX)ImmunityBioCompany update

Methods developed and validated to establish the “World Bank of NK Cells” from healthy donors and cancer patients Single apheresis yields up to 5 billion (5×10 9) highly pure activated memory cytokine-enhanced NK cells (M-ceNK), providing up to 8-10 doses of M-ceNK product per patient Manufacturing

Related news

ImmunityBio

Immune-Based Cancer Therapies ImmunityBio develops therapies that activate innate and adaptive immune responses against cancer. Its platform combines cytokine biology, cell therapy and immunotherapy combinations. ANKTIVA ANKTIVA is an IL-15 superagonist approved with BCG for selected patients with BCG-unresponsive non-muscle-invasive...

Recent company news

Stock data

Close
7.79 USD
Market cap
7.57B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States